Predictors of Death during Tuberculosis Treatment in TB/HIV Co-Infected Patients in Malaysia

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ismail, Ismawati ^a,b   Bulgiba, Awang ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b MINISTRY OF HEALTH   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INDIAN; INFECTION CONTROL; LEUKOCYTE COUNT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAY; MALAYSIA; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MORTALITY; OPPORTUNISTIC INFECTION; PUBLIC HOSPITAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; MALAYSIA; MALE; MIDDLE AGED; PROGNOSIS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84881530958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073250     Document Type: Article

References (41)

1. World Health Organization (2004) TB/HIV- A clinical manual. 2nd Edition. Geneva, Switzerland: World Health Organization.
2. World Health Organization (2012) Global Tuberculosis Report 2012 Geneva, Switzerland: World Health Organization.
3. World Health Organization (2011) Global tuberculosis control: Who, eds. Geneva, Switzerland: World Health Organization Report 2011.
4. Ministry of Health Malaysia (2011). atl Strateg Plan TB Control Malays: pp. 2011-2015:.
5. Sanguanwongse NMD, Cain KPMD, Suriya PMS, Nateniyom SMD, Yamada NMD, et al. (2008) Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 48: 181-189. doi:10.1097/QAI.0b013e318177594e. PubMed: 18520676.
6. Sungkanuparph S, Eampokalap B, Chottanapund S, Thongyen S, Manosuthi W, (2007) Impact of drug-resistant tuberculosis on the survival of HIV-infected patients. Int J Tuberc Lung Dis 11: 325-330. PubMed: 17352100.
7. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S, (2006) Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43: 42-46. doi:10.1097/01.qai.0000230521.86964.86. PubMed: 16885778.
8. Thuy TT, Shah NS, Anh MH, Nghia DT, Thom D, et al. (2007) HIV-associated TB in An Giang Province. Vietnam: pp. 2001-2004: epidemiology and TB treatment outcomes. PloS one 2: e507. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1876817&tool=pmcentrez&rendertype=abstract.
9. Mohammad Z, Naing NN, (2004) Characteristics of HIV-infected tuberculosis patients in Kota Bharu. Hospitals, Available: pp. 1998 to 2001. Southeast Asian J Trop Med Public Health 35:140-143.
10. Nissapatorn V, Kuppusamy I, Sim BLH, Quek KF, Khairul Anuar A, (2005) Tuberculosis in HIV/AIDS patients: a Malaysian experience. Southeast Asian J Trop Med Public Health 36: 946-953. PubMed: 16295550.
11. Ministry of Health Malaysia (2002) Practice guidelines for the control and management of tuberculosis: 51.
12. World Health Organization (2010) Treatment of tuberculosis guidelines. p. 147. Available: http://www.who.int/tb/publications/2010/9789241547833/en/index.html. Accessed 12 September 2012.
13. Ministry of Health Malaysia (2012) TB Control Program in Malaysia, Annual Report 2011 Kuala Lumpur: Malaysia Ministry of Health.
14. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, et al. (1995) The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg 89: 78-82. doi:10.1016/0035-9203(95)90668-1. PubMed: 7747316.
15. Harries, a D, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR,et al (1998) Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg 92: 343-347. doi:10.1016/S0035-9203(98)91036-7. PubMed: 9861414.
16. Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, et al. (2006) Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 75: 1027-1033. PubMed: 17172361.
17. Mugusi FM, Mehta S, Villamor E, Urassa W, Saathoff E, et al. (2009) Factors associated with mortality in HIV-infected and uninfected patients with pulmonary tuberculosis. BMC Public Health 9: 409. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2779816&tool=pmcentrez&rendertype=abstract. Accessed: 25 September 2012. doi:10.1186/1471-2458-9-409. PubMed: 19909501.
18. Quy HT, Cobelens FGJ, Lan NTN, Buu TN, Lambregts CSB, et al. (2006) Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 10: 45-51. PubMed: 16466036.
19. Van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, et al. (1998) Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 2: 547-552. PubMed: 9661820.
20. Morris CD, Bird a R, Nell H (1989) The haematological and biochemical changes in severe pulmonary tuberculosis. The Quarterly Journal of Medicine 73: 1151-1159.
21. Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977. doi:10.1038/nature09247. PubMed: 20725040.
22. Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, et al. (2006) Changes in leukocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol 145: 252-260. doi:10.1111/j.1365-2249.2006.03144.x. PubMed: 16879244.
23. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G, et al. (2012) Tuberculosis and HIV Co-Infection. PLOS Pathog 8: e1002464. Available: http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1002464. PubMed: 22363214.
24. Català L, Orcau A, García de Olalla P, Millet JP, Rodríguez-Mondragón A, et al. (2011) Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment. Int J Tuberc Lung Dis 15: 263-269. PubMed: 21219692.
25. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, et al. (2009) Mortality from HIV and TB co-infections is higher in Eastern Europe than in Western Europe and Argentina. AIDS 23: 2485-2495. doi:10.1097/QAD.0b013e3283326879. PubMed: 19898216.
26. Palmieri F, Pellicelli AM, Girardi E, De Felici AP, De Mori P, et al. (1999) Negative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. Infection 27: 331-334. doi:10.1007/s150100050038. PubMed: 10624592.
27. Girardi E, Palmieri F, Angeletti C, Vanacore P, Matteelli A, et al. (2012) Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis. Clin Dev Immunol, 2012(2012): 931325. PubMed: 22489253.
28. Whalen C, Horsburgh CR Jr,., Hom D, Lahart C, Simberkoff M, et al. (1997) Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 11: 455-460. doi:10.1097/00002030-199704000-00008. PubMed: 9084792.
29. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, et al. (2012) Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLOS ONE 7: e47542. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3472995&tool=pmcentrez&rendertype=abstract. Accessed: 18 June 2013. doi:10.1371/journal.pone.0047542. PubMed: 23094059.
30. Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, et al. (2001) Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 26: 326-331. doi:10.1097/00042560-200104010-00006. PubMed: 11317073.
31. Gadkowski LB, Hamilton CD, Allen M, Fortenberry ER, Luffman J, et al. (2009) HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. AIDS Patient Care STDs 23: 845-851. doi:10.1089/apc.2009.0030. PubMed: 19803793.
32. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, et al. (2009) HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 9: 42. Available: http://www.ncbi.nlm.nih.gov/pubmed/19364398. doi:10.1186/1471-2334-9-42. PubMed: 19364398.
33. Velasco MMDP, Castilla VMDP, Sanz JMDP, Gaspar GMDP, Emdp, Condeset al. (2009) Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 50: 148-152. doi:10.1097/QAI.0b013e31819367e7. PubMed: 19131895.
34. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362: 697-706. doi:10.1056/NEJMoa0905848. PubMed: 20181971.
35. Blanc FX, Sok T, Laureillard D, (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 16: 1471-1481. Available: http://www.nejm.org/doi/full/10.1056/NEJMoa1013911. Accessed: 24 May 2013. PubMed: 22010913.
36. Havlir DV, Kendall Ma, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482-1491. doi:10.1056/NEJMoa1013607. PubMed: 22010914.
37. Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, et al. (2011) A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4+ T-cell counts of ≥ 350 cells/μL. J Infect Dis 204: 884-892. doi:10.1093/infdis/jir503. PubMed: 21849285.
38. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492-1501. doi:10.1056/NEJMoa1014181. PubMed: 22010915.
39. Alpert PL, Munsiff SS, Gourevitch MN, Greenberg B, Klein RS, (1997) A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 24: 661-668. doi:10.1093/clind/24.4.661. PubMed: 9145741.
40. Shafer RW, Bloch AB, Larkin C, Vasudavan V, Seligman S, et al. (1996) Predictors of survival in HIV-infected tuberculosis patients. AIDS 10: 269-272. Available doi:10.1097/00002030-199603000-00005. PubMed: 8882666.
41. Porter JDH, (1996) Mycobacteriosis and HIV infection: the new public health challenge. J Antimicrob Chemother 37: 113-120. doi:10.1093/jac/37.suppl_B.113. PubMed: 8818834.